David Dai Analyst PerformanceAnalyst at Sanford C. BernsteinDavid Dai is a stock analyst at Sanford C. Bernstein focused in the medical sector, covering 19 publicly traded companies. Over the past year, David Dai has issued 41 stock ratings, including buy and hold recommendations. While full access to David Dai's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights David Dai's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings45 Last 6 YearsBuy Recommendations72.09% 31 Buy RatingsCompanies Covered19 Unique Companies Ratings Distribution43RatingsDistribution of strong buy, buy, hold, and sell ratings by David Dai.RatingPercentageCount Strong Buy0.0%0 ratings Buy72.1%30 ratings Hold27.9%12 ratings Sell0.0%0 ratingsOut of 43 total stock ratings issued by David Dai at Sanford C. Bernstein, the majority (72.1%) have been Buy recommendations, followed by 27.9% Hold.Best & Worst CallsBest Call000.0%CGEMMay 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%BIDUApr 2020Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ89.5% of companies on NASDAQ17 companiesNYSEAMERICAN5.3% of companies on NYSEAMERICAN1 companyNYSE5.3% of companies on NYSE1 companyDavid Dai, an analyst at Sanford C. Bernstein, currently covers 19 companies listed on NASDAQ, NYSEAMERICAN and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical15 companies78.9%Computer and Technology3 companies15.8%Consumer Discretionary1 company5.3%David Dai of Sanford C. Bernstein specializes in stock coverage within the Medical sector, with additional focus on Computer and Technology and Consumer Discretionary companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE13 companies68.4%ELEC COMP - SEMIC1 company5.3%SEQPT - WAFER FAB1 company5.3%SURGICAL & MEDICAL INSTRUMENTS1 company5.3%AUDIO/VIDEO PRD1 company5.3%MED - DRUGS1 company5.3%INTERNET SERVICES1 company5.3% David Dai's Ratings History at Sanford C. Bernstein Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsARMARM6/17/2026Set Price Target$422.90$500.00$0.0000.00% ROIARMARM6/17/2026Reiterated Rating$396.34Outperform$0.0000.00% ROIASMLASML6/15/2026Reiterated Rating$1,868.60Buy$0.0000.00% ROISNDXSyndax Pharmaceuticals6/12/2026Reiterated Rating$17.91Buy$0.0000.00% ROINUVLNuvalent6/10/2026Downgrade$123.25$124.00Neutral$0.0000.00% ROINUVLNuvalent6/10/2026Downgrade$123.25$124.00Neutral$0.0000.00% ROICLDXCelldex Therapeutics6/10/2026Boost Price Target$29.41$45.00Buy$0.0000.00% ROIBNTXBioNTech5/27/2026Upgrade$92.25$135.00Buy$0.0000.00% ROIASMLASML5/25/2026Reiterated Rating$1,632.90Buy$0.0000.00% ROIARMARM5/18/2026Initiated Coverage$209.16$300.00Outperform$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. ARMARM5/18/2026Initiated Coverage$215.12$300.00Outperform$0.0000.00% ROISNDXSyndax Pharmaceuticals5/13/2026Lower Price Target$20.12$37.00Buy$0.0000.00% ROIASMLASML4/23/2026Reiterated Rating$1,454.97Buy$0.0000.00% ROIJANXJanux Therapeutics4/15/2026Downgrade$15.24$15.00Neutral$0.0000.00% ROIASMLASML3/26/2026Boost Price Target$1,393.89$1,971.00Buy$0.0000.00% ROIJSPRJasper Therapeutics3/23/2026Initiated Coverage$1.23Neutral$0.0000.00% ROICATXPerspective Therapeutics3/18/2026Boost Price Target$4.95$8.00Buy$0.0000.00% ROISONYSony3/17/2026Reiterated Rating$21.67$22.00Market Perform$0.0000.00% ROISONYSony3/16/2026Downgrade$20.92$22.00Market Perform$0.0000.00% ROIKURAKura Oncology3/13/2026Reiterated Rating$8.61$15.00Buy$0.0000.00% ROIIOVAIovance Biotherapeutics3/5/2026Boost Price Target$4.16$4.00Neutral$0.0000.00% ROIKYMRKymera Therapeutics3/3/2026Boost Price Target$88.16$128.00Buy$0.0000.00% ROIASMLASML2/25/2026Reiterated Rating$1,497.80Buy$0.0000.00% ROIASMLASML1/29/2026Set Price Target$1,422.92$1,911.00$0.0000.00% ROIASMLASML1/22/2026Boost Price Target$1,360.09$1,642.00Outperform$0.0000.00% ROIASMLASML1/16/2026Reiterated Rating$1,358.57Buy$0.0000.00% ROISONYSony1/14/2026Reiterated Rating$24.41$30.00Outperform$0.0000.00% ROISONYSony1/14/2026Set Price Target$24.41$30.00Outperform$0.0000.00% ROIASMLASML1/5/2026Upgrade$1,163.78Buy$0.0000.00% ROIASMLASML1/4/2026Set Price Target$1,163.78$1,528.00Outperform$0.0000.00% ROINUVLNuvalent12/17/2025Reiterated Rating$102.44Buy$0.0000.00% ROIBNTXBioNTech12/4/2025Upgrade$97.28Hold$0.0000.00% ROIJANXJanux Therapeutics12/2/2025Reiterated Rating$17.97$57.00Buy$0.0000.00% ROIKURAKura Oncology11/14/2025Boost Price Target$12.35$16.00Buy$0.0000.00% ROIBNTXBioNTech11/6/2025Boost Price Target$103.43$117.00Neutral$0.0000.00% ROISNDXSyndax Pharmaceuticals11/4/2025Boost Price Target$14.98$38.00Buy$0.0000.00% ROINUVLNuvalent10/31/2025Boost Price Target$98.17$132.00Buy$0.0000.00% ROIMRUSMerus9/30/2025Downgrade$93.67$97.00Neutral$0.0000.00% ROISNDXSyndax Pharmaceuticals7/15/2025Lower Price Target$9.26$35.00Buy$0.0000.00% ROINRIXNurix Therapeutics7/10/2025Lower Price Target$12.67$26.00Buy$0.0000.00% ROIA drilling crew just broke a record nobody expected (Ad)A drilling crew in Beaver County, Utah hit 15,765 feet of solid granite in 16 days - a job the Department of Energy projected would take 64. They reached DOE's 2035 performance targets twelve years early, cutting costs in half within 18 months. When Congress moved to cut solar and wind tax credits, this energy source kept its full credits through 2033. One company has been building in this space for sixty years, and a July 4th catalyst is now 12 days away.See the company at the center of Project FORGE right nowSMMTSummit Therapeutics7/1/2025Initiated Coverage$21.28$30.00Buy$0.0000.00% ROIBPMCBlueprint Medicines6/5/2025Boost Price Target$128.10$129.00Neutral$0.0000.00% ROIIOVAIovance Biotherapeutics5/16/2025Downgrade$1.76$2.00Neutral$0.0000.00% ROICGEMCullinan Therapeutics5/12/2025Lower Price Target$7.89$24.00Buy$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenJefferies Financial GroupThe Goldman Sachs GroupWeiss RatingsUBS GroupCitigroupBarclaysMorgan StanleyWells Fargo & CompanyRoyal Bank Of CanadaJPMorgan Chase & Co.TD CowenTruist FinancialPiper SandlerDeutsche Bank Aktiengesellschaft Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
